

MODULAR EDUCATION PROGRAMME IN TOXICOLOGICAL PATHOLOGY

MODULE 3: CARCINOGENESIS

Cambridge

22nd – 26th March 2010

PROVISIONAL PROGRAMME

Monday 22nd March

- 1200 - 1315 Registration & Lunch**
- 1315 - 1330 Welcome**
Eric Jacquinet, Scientific Organiser
- 1330 - 1430 Cancer in man & the history of carcinogenesis - Lecture**
Chris Foster, University of Liverpool, UK
- 1430 - 1530 In-vitro mutagenicity testing - initial steps in assessing the potential carcinogenicity of novel chemicals & further investigation - Lecture**
Fiona Spence, Pfizer, UK
- 1530 - 1600 Break**
- 1600 - 1700 Initiation & promotion/genotoxic vs non-genotoxic mechanisms of carcinogenesis - Lecture**
Shirley Price, University of Surrey, UK
- 1800 - 1900 Informal gathering at a local hotel**

Tuesday 23rd March

- 0900 - 1000 Molecular mechanisms of cancer (i) - oncogenes, repressors etc - Lecture**
Kevin Chipman, University of Birmingham, UK
- 1000 - 1100 Molecular mechanisms of cancer (ii) - oncogenes, repressors etc - Lecture**
Kevin Chipman, University of Birmingham, UK
- 1100 - 1130 Break**
- 1130 - 1230 Cancer & inflammation - Lecture**
Fran Balkwill, University of London, UK
- 1230 - 1330 Lunch**
- 1330 - 1430 Invasion & metastases – Lecture**
Ian Hart, Barts & The London School of Medicine & Dentistry, UK
- 1430 - 1530 Introduction to RITA – Lecture & Practical**
Thomas Nolte, RITA, Germany

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Tuesday 23rd March (continued)

1530 - 1600 Break

1600 - 1700 Introduction to RITA – Lecture & Practical
Thomas Nolte, RITA, Germany

Wednesday 24th March

0900 - 1000 An overview of animal models of cancer - Lecture
John Foster, AstraZeneca, UK

1000 - 1100 An overview of animal models of cancer - Practical
John Foster, AstraZeneca, UK

1100 - 1130 Break

1130 - 1230 The use of statistics in carcinogenicity testing - Lecture
Ian Taylor, Huntingdon Life Sciences, UK

1230 - 1330 Lunch

1330 - 1430 Use of immunIHC for tumour characterisation - Lecture
Richard Haworth, GSK, UK

1430 - 1530 Design & interpretation of carcinogenicity studies - Lecture
Dan Morton, Pfizer, USA

1530 - 1600 Break

1600 - 1700 Predictive models of carcinogenicity – Lecture
John Foster, AstraZeneca, UK

Thursday 24th March

0900 - 1000 Use of genetically engineering mice in carcinogenicity studies - Lecture
Dan Morton, Pfizer, USA

1000 - 1100 Hyperplasia to neoplasia in rats – common lesions - Lecture
Chris Barton, Covance Laboratories, UK

1100 - 1130 Break

1130 - 1230 Hyperplasia to neoplasia in rats – common lesions - Practical
Chris Barton, Covance Laboratories, UK

1230 - 1330 Lunch

1330 - 1430 Significance & interpretation of neoplasia in laboratory animals - Lecture
Vasanthi Mowat, Huntingdon Life Sciences, UK

1430 - 1530 Hyperplasia to neoplasia in mice - Practical
Vasanthi Mowat, Huntingdon Life Sciences, UK

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Thursday 24th March (continued)

1530 - 1600 Break

1600 - 1700 Case study/data evaluation
Andrea Terron, GSK, Italy

1900 for 1930 Course Dinner

Friday 25th March

0900 - 1000 The relevance of rodent specific tumours - Lecture
Vasanthi Mowat, Huntingdon Life Sciences, UK

1000 - 1030 Break

1030 - 1200 The regulatory view of carcinogenicity testing - Lecture
David Jones, MHRA, UK

1200 - 1215 Closing remarks
Eric Jacquinet, Scientific Organiser